Why GLP-1 patients quit treatment — and what clinics can do about it

Adherence is the single biggest determinant of outcomes in weight-loss programs. Not the protocol. Not the drug. Not the prescriber. Adherence. And most programs fail not because the intervention is weak, but because they ignore where the patient actually is — psychologically — when treatment begins.

Robust evidence from major clinical journals confirms what experienced clinicians already know: in GLP-1 therapy, the patient who stays in treatment is the patient who succeeds. The patient who quits — and roughly two in three do — accounts for most of what a weight-loss program loses in clinical and economic value.

The question, then, is not how to find better patients. It is how to receive the patients you already have differently.

Two patients, same program

Picture two people walking into the same medical weight-loss clinic on the same day.

Ana has tried several diets. She's tired of failing. Something in her knows she has to do something.

Carlos was referred by his GP. He doesn't talk about his weight, and he hasn't stepped on a scale in two years.

Both qualify for the program. But treating them the same way is the mistake that loses them both.

The difference between sustained engagement and early dropout often has nothing to do with the treatment itself. It has to do with the psychological stage the patient occupies when they arrive. This is the territory mapped by one of behavioral science's most validated frameworks: the Transtheoretical Model of Change (Prochaska & DiClemente, 1983).

The principle: not everyone is ready to change

The Transtheoretical Model describes behavior change as a process unfolding through five stages:

• Precontemplation — the patient does not recognize the problem, or actively avoids thinking about it
• Contemplation — the problem is recognized, but ambivalence rules
• Preparation — planning starts; small changes appear
• Action — behaviors change
• Maintenance — change becomes durable

The model is widely validated across public health and eating-behavior research (Prochaska & Velicer, 1997). In obesity care specifically, interventions matched to stage of readiness consistently produce better adherence and outcomes than one-size-fits-all programs (Teixeira et al., 2012).

The implication is uncomfortable for any program built around standard protocols: low adherence in weight-loss programs is often not a treatment problem. It is a stage-mismatch problem.

The invisible obstacle: the Ostrich Effect

Before stage-matching can even begin, there is a quieter problem. Many patients avoid the very information their treatment depends on:

• They avoid the scale
• They avoid looking at lab results
• They avoid discussing weight with clinicians

This is the Ostrich Effect — the tendency to selectively avoid information that may be threatening (Karlsson, Loewenstein & Seppi, 2009). In weight-loss treatment, this is not laziness or lack of interest. It is a protective mechanism against shame, fear of failure, and the feeling of losing control.

An effective program does not force confrontation. It reduces the threat of the information.

Three phases: invitation, assessment, fit

Phase 1 — Universal invitation

Everyone interested is welcomed into the program. This matters for two reasons. First, it removes stigma: the program is not a club for the already-motivated. Second, it captures patients at every stage of the journey, not just the action-ready ones.

The framing of the invitation does the work:

This program is not about changing everything at once. It's about understanding your body better, and taking small steps that make sense for you.

Notice what's absent — no language about weight, failure, or transformation. Health, energy, longevity. The program is positioned as a tool for self-knowledge, not judgment.

Phase 2 — Assessment of readiness

After accepting, the patient completes a structured questionnaire. The instrument is not a screening tool — it is a routing tool. Questions assess:

• Self-perception of weight and health
• History of past attempts
• Readiness to make changes
• Emotional reaction to self-monitoring

Examples of the kind of question that surfaces stage:

• "Have you been thinking about changing something related to your weight?"
• "Have you tried to lose weight in the past six months?"
• "How do you feel when you step on the scale?"
• "Do you believe tracking your health data could help you?"

The patient is then assigned to one of the five stages. This is not exclusion. It is calibration.

Phase 3 — Functional fit, not selection

Everyone stays in the program, but the program speaks to each patient differently. The access does not change. The conversation does.

Adapting the program to the stage

Precontemplation: reduce the threat

These patients avoid monitoring. Demanding daily weigh-ins is the fastest way to lose them.

The strategy is indirect: introduce data through energy, sleep, and movement before weight. Reinforce autonomy. The message is permission, not pressure:

You don't need to change anything yet. We're just going to start by understanding how your body actually works.

Contemplation: work with ambivalence

These patients see the problem but are afraid of the answer.

The strategy is to validate the ambivalence — discuss the pros and cons of change openly, treat self-monitoring as a tool rather than a verdict:

Preparation: structure the action

The patient is ready. Now the work is making the structure feel achievable.

The strategy is to introduce regular weighing, explain the role of monitoring tools (Sinque, in the EW2Health stack), set small goals:

Action and maintenance: reinforce consistency

These patients benefit most directly from monitoring. The data correlates with their GLP-1 dosing, helps prevent the early-treatment plateau, and builds the durability that protects against relapse:

Without stage-adaptation, adherence in weight-loss programs tends to fall sharply in the first weeks. With it, the curve flattens — and the 65% dropout rate that characterizes standard care begins to look avoidable.

The role of monitoring: bridge, not surveillance

The biggest risk in any monitoring-led program is that the patient experiences the data as external control. As judgment. As pressure to perform.

The correct positioning is the opposite. Monitoring is a bridge between the patient and their own body — especially in GLP-1 treatment, where individual response varies and the difference between a working dose and a stalling one shows up in patterns the patient cannot see unaided.

Without data, the patient operates in the dark. With data, they gain clarity, and from clarity, control.

What selection actually means

Traditional weight-loss programs fail because they treat every patient identically. The model proposed here does the opposite:

• Everyone is invited
• Each patient is met where they are
• The program adapts to the patient — not the patient to the program

The result is what the data shows when the model is applied: less early dropout, less anxiety about monitoring, less treatment resistance — and more engagement, more sustained GLP-1 adherence, more measurable progress.

Referências

• Prochaska, J. O., & DiClemente, C. C. (1983). Stages and processes of self-change of smoking. Journal of Consulting and Clinical Psychology.
• Prochaska, J. O., & Velicer, W. F. (1997). The Transtheoretical Model of Health Behavior Change. American Journal of Health Promotion.
• Teixeira, P. J., Carraça, E. V., Markland, D., Silva, M. N., & Ryan, R. M. (2012). Exercise, physical activity, and self-determination theory: A systematic review. International Journal of Behavioral Nutrition and Physical Activity.
• Karlsson, N., Loewenstein, G., & Seppi, D. (2009). The Ostrich Effect: Selective attention to information. Journal of Risk and Uncertainty.